NASDAQ: VANIVivani Medical Inc Stock
$1.67-0.03 (-1.76%)
Updated Apr 22, 2024
VANI Price
$1.67
Fair Value Price
-$0.00
Market Cap
$91.81M
52 Week Low
$0.84
52 Week High
$7.80
P/E
-3.34x
P/B
4.42x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$25.65M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.21
Operating Cash Flow
-$24M
Beta
1.13
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
VANI Overview
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VANI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VANI ($1.67) is overvalued by 202,301.21% relative to our estimate of its Fair Value price of -$0.00 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VANI ($1.67) is not significantly undervalued (202,301.21%) relative to our estimate of its Fair Value price of -$0.00 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VANI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VANI due diligence checks available for Premium users.
Be the first to know about important VANI news, forecast changes, insider trades & much more!
VANI News
Valuation
VANI fair value
Fair Value of VANI stock based on Discounted Cash Flow (DCF)
Price
$1.67
Fair Value
-$0.00
Undervalued by
202,301.21%
VANI ($1.67) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VANI ($1.67) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VANI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VANI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.34x
Industry
16.21x
Market
41x
VANI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.42x
Industry
5.82x
VANI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VANI's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.0M
Profit Margin
0%
VANI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$45.8M
Liabilities
$25.0M
Debt to equity
1.21
VANI's short-term assets ($23.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VANI's short-term assets ($23.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VANI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VANI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.5M
Investing
-$743.0k
Financing
$23.0k
VANI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VANI vs Biotech Stocks
Vivani Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.